KineMed will employ its translational medicine technologies to establish a disease target for a selected drug candidate.

KineMed and Bayer Healthcare signed an agreement to discover new therapeutic applications. “The collaboration with Bayer Healthcare is an important opportunity for us to discover new indications for promising compounds and to work with Bayer Healthcare to pursue clinical development,” comments David Fineman, president and CEO of KineMed.

KineMed will identify new therapeutic utilities by applying its translational medicine technologies, AquaTag™ and KineMarker™. Once a disease target is established for a selected drug candidate, the companies will jointly determine the best development and commercialization path.

“This is in fact,” points out Finemen, “the third indications discovery deal we have announced in the past year, each of which gives us the option to move into more advanced product development.”

Previous articleAntisense and Isis Extend Pact
Next articleTransgenomic and Fiuotecnica Renew Cardiovascular Disease Gene Panel Agreement